MRI-Guided radiation: a sharper aim for HPV cancers?
NCT ID NCT03634267
First seen Jun 24, 2026 · Last updated Sep 16, 2026 · Updated 3 times
Summary
This early-phase trial tests whether using MRI scans to guide the placement of internal radiation (brachytherapy) can improve treatment for women with advanced cervical or vaginal cancers linked to HPV. The study involves 26 participants and compares MRI-guided placement to standard ultrasound or freehand methods. The goal is to see if MRI helps deliver a more precise radiation dose to the tumor while sparing nearby organs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Internal radiation therapy (brachytherapy) guided by MRI
- What this could lead to
- If successful, this approach could make brachytherapy more precise, potentially improving tumor control and reducing side effects for women with cervical or vaginal cancer.
- What could go wrong
- This is a very early phase 1 trial with only 26 participants, so results may not apply to all patients. The technique requires MRI-compatible equipment and may not be feasible for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
26 people
The number who actually took part.
- Started
-
Aug 2018
- Finished
-
Aug 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women with stage 1B2-IVA cervical cancer recommended to receive definitive chemoradiation including brachytherapy; or * Women with stage II-IVA vaginal cancer recommended to receive definitive chemoradiation including brachytherapy. Exclusion Criteria: * Patient or tumor anatomy that requires use of a non-MRI-compatible applicator. * Patients with implantable cardioverter-defibrillator, pacemaker or other implanted device or medical condition which precludes MRI acquisition.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-associated vaginal carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple education push prevent 400,000 cancers?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- At-Home cervical cancer screening could save lives in rural uganda
- Could a delayed booster still protect against HPV?
- Custom-Made cancer vaccine shows promise in advanced tumors